Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy

Malignant glioma, or glioblastoma, is the most common and lethal form of brain tumor with a median survival time of 15 months. The established therapeutic regimen includes a tripartite therapy of surgical resection followed by radiation and temozolomide (TMZ) chemotherapy, concurrently with radiatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Sengupta, Sadhak, Marrinan, Jaclyn, Frishman, Caroline, Sampath, Prakash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3486128/
https://www.ncbi.nlm.nih.gov/pubmed/23133490
http://dx.doi.org/10.1155/2012/831090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3486128/
https://www.ncbi.nlm.nih.gov/pubmed/23133490
http://dx.doi.org/10.1155/2012/831090

Ejemplares similares